Abiraterone acetate - Druggability TechnologiesAlternative Names: DRGT 45
Latest Information Update: 04 Jan 2017
At a glance
- Originator Druggability Technologies
- Class Androstenols; Antiandrogens; Antineoplastics; Small molecules
- Mechanism of Action CYP17A1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- Phase I Prostate cancer